查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856987

全球基因靜默市場：預測至2032年－依產品/服務、機制、技術、應用、最終使用者及地區進行分析

Gene Silencing Market Forecasts to 2032 - Global Analysis By Product & Service, Mechanism, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球基因靜默市場規模將達到 114.8 億美元，到 2032 年將達到 320.7 億美元，預測期內複合年成長率為 15.8%。

基因靜默是一種天然的生物學過程，它透過阻止特定基因產生蛋白質或其他基因產物來控制基因表現。基因靜默發生在轉錄或轉錄後水平，有效地「關閉」基因，而無需改變其DNA序列。 RNARNA干擾（RNAi）、DNA甲基化和組蛋白修飾等機制在這過程中扮演重要角色。基因靜默有助於調節細胞功能、維持基因組穩定性以及抵抗病毒和轉座因子。它也被廣泛應用於生物技術和醫學領域，用於研究基因功能和開發遺傳性感染疾病的治療方法。

遺傳性疾病和慢性病發生率上升

RNA干擾（RNAi）、反義寡核苷酸（ASO）和基於CRISPR的定序平台能夠對致病基因進行標靶控制。製藥公司和生技新興企業正在拓展其定序研發管線，以應對亨廷頓氏舞蹈症、肌萎縮側索硬化症（ALS）和遺傳性癌症等疾病。與基因組分析和遞送系統的整合能夠提高治療的精準性和組織標靶性。個人化醫療和孤兒藥計畫正在推動對非侵入性、持久性干預措施的需求。這些因素正在推動基因靜默系統的平台創新和臨床應用。

安全性和免疫抗原性問題

脫靶效應、免疫活化和毒性等風險會影響平台可靠性和患者療效。病毒載體和脂質奈米顆粒等遞送載體必須在療效、生物相容性和清除率之間取得平衡。監管機構要求對基因沉默候選藥物進行廣泛的臨床前檢驗和長期安全性數據核准定序。臨床試驗的延誤和不利事件的報告持續阻礙投資者信心和研發管線的推進。這些限制因素阻礙了基因沉默技術在高風險和免疫敏感治療領域的應用。

臨床驗證和核准成功

FDA和EMA對基於RNAi的藥物（例如patisiran和givosiran）的核准，檢驗了其治療效果和商業性可行性。臨床試驗表明，這些藥物能夠持續抑制基因表達，減輕症狀，並改善罕見疾病和慢性病的生物標記。學術界和產業界的贊助商正在加速推進RNAi在癌症、代謝性疾病和感染疾病領域的適應症拓展。製藥業的合作與授權協議正在推動對可擴展、受監管的基因定序平台的需求。這些趨勢正在促進臨床轉化和治療方法多樣化的發展。

智慧財產權與市場競爭

專利糾紛、許可限制和自由營運方面的挑戰限制了創新和市場准入。早期參與企業和專有遞送系統的主導地位限制了新興企業和學術衍生企業的進入。智慧財產權格局的分散化使跨國商業化和策略聯盟變得複雜。來自 CRISPR、鹼基編輯和表觀遺傳調控平台的競爭壓力降低了投資者對傳統定序方法的關注。這些風險持續限制該平台的擴充性及其在治療市場的長期地位。

新冠疫情的影響：

疫情擾亂了基因靜默計畫的臨床試驗、生產和監管進程。封鎖和資源重新分配延緩了罕見疾病和腫瘤臨床試驗的患者招募和數據收集。然而，由於mRNA疫苗的成功以及大眾對基因醫學的認知度提高，人們對基於RNA的平台產生了濃厚的興趣。對遞送系統、免疫抗原性緩解和遠端監測的投資加速了平台創新。疫情後的策略已將基因靜默作為精準醫療和治療韌性的核心支柱。這種轉變加強了對定序技術的長期投資和監管參與。

預計在預測期內， RNA干擾（RNAi）領域將是最大的細分市場。

由於其高效的機制、成熟的臨床應用以及在多種疾病領域的廣泛適用性，RNA干擾（RNAi）領域預計將在預測期內佔據最大的市場佔有率。 RNAi平台利用siRNA和shRNA構建體以高特異性和持久性沉默標靶基因。脂質奈米顆粒遞送以及與組織特異性啟動子的整合可提高治療的精確度和安全性。核准的RNAi藥物和處於後期研發階段的候選藥物已在肝病學、神經病學和眼科學等領域展現出療效。製藥研發和學術研究對可擴展和模組化RNAi平台的需求日益成長。

預計在預測期內，軟體和生物資訊學工具領域將實現最高的複合年成長率。

軟體與生物資訊學工具領域預計將在預測期內呈現最高成長率，因為數據複雜性和標靶驗證推動了對高階分析的需求。平台支援RNAi、ASO和CRISPR工作流程中的序列設計、脫靶預測和遞送最佳化。人工智慧和機器學習演算法能夠實現生物標記發現、毒性建模以及跨臨床隊列的患者分層。雲端基礎的基礎設施和模組化流程提高了研究和商業環境中的可擴展性和可訪問性。對互通性、安全且經過臨床檢驗的生物資訊工具的需求正在不斷成長，以滿足定序技術開發和監管申報的需求。

比最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的生物技術生態系統、清晰的監管環境和完善的臨床基礎設施。美國和加拿大的公司正在罕見疾病、腫瘤和神經病學計畫中部署基因靜默平台，並整合了交付和分析功能。對基因組醫學的投資、產學合作以及美國食品藥物管理局（FDA）的參與，都為平台的擴充性和檢驗提供了支持。領先的治療藥物開發商、合約研究組織（CRO）和研究機構的存在，正在推動創新和標準化。這些因素共同促成了北美在基因靜默的商業化和臨床應用領域的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療現代化、遺傳疾病負擔以及生物技術投資在該地區各國經濟中的融合發展。中國、印度、日本和韓國等國家正在公共衛生計畫、學術研究和臨床試驗中推廣基因靜默平台。政府支持的舉措正在推動RNA和寡核苷酸療法的基礎建設、新興企業孵化以及國際研究合作。本地企業正在提供經濟高效且符合當地實際情況的解決方案，以滿足疾病特徵和合規性需求。這些趨勢正在推動該地區基因靜默創新和療法應用的成長。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球基因靜默市場（依產品和服務分類）

  • 試劑和試劑盒
  • 裝置
  • 寡核苷酸和RNA分子
  • 軟體、生物資訊學工具
  • 基因靜默服務
  • 其他產品和服務

6. 全球基因靜默市場依機制分類

  • 轉錄基因靜默
  • 轉錄後基因靜默
  • 表觀遺傳調控

7. 全球基因靜默市場（依技術分類）

  • RNA干擾（RNAi）
  • 反義寡核苷酸（ASO）
  • CRISPR干擾（CRISPRi）
  • 表觀遺傳定序
  • siRNA/shRNA遞送系統

8. 全球基因靜默市場（依應用領域分類）

  • 藥物發現與開發
  • 治療藥物生產
  • 功能基因體學
  • 目標檢驗
  • 疾病模型
  • 其他用途

9. 全球基因靜默市場（依最終用戶分類）

  • 製藥和生物技術公司
  • 學術研究機構
  • CRO/CDMO
  • 醫院和診斷實驗室
  • 其他最終用戶

第10章 全球基因靜默市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Sirnaomics
  • Arbutus Biopharma
  • Olix Pharmaceuticals
  • Benitec Biopharma
  • Sylentis
  • Genevant Sciences
  • RXi Pharmaceuticals
  • Intellia Therapeutics
  • Editas Medicine
  • Beam Therapeutics
Product Code: SMRC31852

According to Stratistics MRC, the Global Gene Silencing Market is accounted for $11.48 billion in 2025 and is expected to reach $32.07 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Gene silencing is a natural biological process that regulates gene expression by preventing specific genes from producing proteins or other gene products. It can occur at the transcriptional or post-transcriptional level, effectively "turning off" a gene without altering its DNA sequence. Mechanisms such as RNA interference (RNAi), DNA methylation, and histone modification play key roles in this process. Gene silencing helps control cellular functions, maintain genome stability, and defend against viruses or transposable elements. It is also widely used in biotechnology and medicine for studying gene function and developing treatments for genetic and infectious diseases.

Market Dynamics:

Driver:

Rising prevalence of genetic & chronic diseases

RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based silencing platforms enable targeted modulation of disease-causing genes. Pharmaceutical firms and biotech startups are scaling silencing pipelines to address conditions such as Huntington's, ALS, and hereditary cancers. Integration with genomic profiling and delivery systems enhances therapeutic precision and tissue targeting. Demand for non-invasive and durable interventions is rising across personalized medicine and orphan drug programs. These dynamics are propelling platform innovation and clinical adoption across gene silencing ecosystems.

Restraint:

Safety and immunogenicity concerns

Off-target effects, immune activation, and toxicity risks degrade platform reliability and patient outcomes. Delivery vehicles such as viral vectors and lipid nanoparticles must balance efficacy with biocompatibility and clearance. Regulatory bodies require extensive preclinical validation and long-term safety data to approve silencing candidates. Clinical trial delays and adverse event reporting continue to hinder investor confidence and pipeline progression. These constraints are hampering adoption across high-risk and immunologically sensitive therapeutic areas.

Opportunity:

Successful clinical proof-of-concept and approvals

FDA and EMA approvals of RNAi-based drugs such as patisiran and givosiran validate therapeutic efficacy and commercial viability. Clinical trials demonstrate durable gene knockdown, symptom reduction, and biomarker improvement across rare and chronic conditions. Expansion into oncology, metabolic, and infectious disease indications is accelerating across academic and industry sponsors. Demand for scalable and regulatory-aligned silencing platforms is rising across pharma partnerships and licensing deals. These trends are fostering growth across clinical translation and therapeutic diversification.

Threat:

Intellectual property & market competition

Patent disputes, licensing restrictions, and freedom-to-operate challenges constrain innovation and market entry. Dominance of early movers and proprietary delivery systems limits access for emerging players and academic spinouts. Fragmented IP landscapes complicate cross-border commercialization and strategic alliances. Competitive pressure from CRISPR, base editing, and epigenetic modulation platforms reduces investor focus on traditional silencing modalities. These risks continue to limit platform scalability and long-term positioning across therapeutic markets.

Covid-19 Impact:

The pandemic disrupted clinical trials, manufacturing, and regulatory timelines across gene silencing programs. Lockdowns and resource reallocation delayed patient recruitment and data collection across rare disease and oncology trials. However, interest in RNA-based platforms surged due to mRNA vaccine success and public awareness of genetic medicine. Investment in delivery systems, immunogenicity mitigation, and remote monitoring accelerated platform innovation. Post-pandemic strategies now include gene silencing as a core pillar of precision medicine and therapeutic resilience. These shifts are reinforcing long-term investment and regulatory engagement across silencing technologies.

The RNA interference (RNAi) segment is expected to be the largest during the forecast period

The RNA interference (RNAi) segment is expected to account for the largest market share during the forecast period due to its validated mechanism, clinical maturity, and broad applicability across disease areas. RNAi platforms use siRNA and shRNA constructs to silence target genes with high specificity and durability. Integration with lipid nanoparticle delivery and tissue-specific promoters enhances therapeutic precision and safety. Approved RNAi drugs and late-stage candidates demonstrate efficacy across liver, nerve, and ocular indications. Demand for scalable and modular RNAi platforms is rising across pharma pipelines and academic research.

The software & bioinformatics tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the software & bioinformatics tools segment is predicted to witness the highest growth rate as data complexity and target validation drive demand for advanced analytics. Platforms support sequence design, off-target prediction, and delivery optimization across RNAi, ASO, and CRISPR workflows. AI and machine learning algorithms enable biomarker discovery, toxicity modelling, and patient stratification across clinical cohorts. Cloud-based infrastructure and modular pipelines improve scalability and accessibility across research and commercial environments. Demand for interoperable, secure, and clinically validated bioinformatics tools is rising across silencing development and regulatory submission.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech ecosystem, regulatory clarity, and clinical infrastructure. U.S. and Canadian firms deploy gene silencing platforms across rare disease, oncology, and neurology programs with integrated delivery and analytics. Investment in genomic medicine, academic-industry partnerships, and FDA engagement supports platform scalability and validation. Presence of leading therapeutic developers, CROs, and research institutions drives innovation and standardization. These factors are propelling North America's leadership in gene silencing commercialization and clinical translation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, genetic disease burden, and biotech investment converge across regional economies. Countries like China, India, Japan, and South Korea scale gene silencing platforms across public health programs, academic research, and clinical trials. Government-backed initiatives support infrastructure development, startup incubation, and international collaboration across RNA and oligonucleotide therapeutics. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. These trends are accelerating regional growth across gene silencing innovation and therapeutic deployment.

Key players in the market

Some of the key players in Gene Silencing Market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Sirnaomics, Arbutus Biopharma, Olix Pharmaceuticals, Benitec Biopharma, Sylentis, Genevant Sciences, RXi Pharmaceuticals, Intellia Therapeutics, Editas Medicine and Beam Therapeutics.

Key Developments:

In September 2025, Ionis secured FDA approvals for TRYNGOLZA (for familial chylomicronemia syndrome, FCS) and DAWNZERA (for hereditary angioedema, HAE), marking a pivotal commercial milestone. Clinical trials showed 72% triglyceride reduction and 85% fewer pancreatitis events for olezarsen, the active compound in TRYNGOLZA. These approvals validate Ionis' RNA-targeted platform and expand its rare disease portfolio.

In February 2025, Alnylam unveiled its TRITON Phase 3 program for nucresiran, a next-generation TTR silencer targeting ATTR-CM and hATTR-PN. The candidate builds on Alnylam's RNAi leadership in amyloidosis and aims to deliver durable knockdown with improved delivery. It complements the company's existing portfolio and supports long-term franchise sustainability in rare diseases.

Product & Services Covered:

  • Reagents & Kits
  • Instruments
  • Oligonucleotides & RNA Molecules
  • Software & Bioinformatics Tools
  • Gene Silencing Services
  • Other Product & Services

Mechanisms Covered:

  • Transcriptional Gene Silencing
  • Post-Transcriptional Gene Silencing
  • Epigenetic Modulation

Technologies Covered:

  • RNA Interference (RNAi)
  • Antisense Oligonucleotides (ASOs)
  • CRISPR Interference (CRISPRi)
  • Epigenetic Silencing
  • siRNA/shRNA Delivery Systems

Applications Covered:

  • Drug Discovery & Development
  • Therapeutics Manufacturing
  • Functional Genomics
  • Target Validation
  • Disease Modeling
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • CROs & CDMOs
  • Hospitals & Diagnostic Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gene Silencing Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Reagents & Kits
  • 5.3 Instruments
  • 5.4 Oligonucleotides & RNA Molecules
  • 5.5 Software & Bioinformatics Tools
  • 5.6 Gene Silencing Services
  • 5.7 Other Product & Services

6 Global Gene Silencing Market, By Mechanism

  • 6.1 Introduction
  • 6.2 Transcriptional Gene Silencing
  • 6.3 Post-Transcriptional Gene Silencing
  • 6.4 Epigenetic Modulation

7 Global Gene Silencing Market, By Technology

  • 7.1 Introduction
  • 7.2 RNA Interference (RNAi)
  • 7.3 Antisense Oligonucleotides (ASOs)
  • 7.4 CRISPR Interference (CRISPRi)
  • 7.5 Epigenetic Silencing
  • 7.6 siRNA/shRNA Delivery Systems

8 Global Gene Silencing Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery & Development
  • 8.3 Therapeutics Manufacturing
  • 8.4 Functional Genomics
  • 8.5 Target Validation
  • 8.6 Disease Modeling
  • 8.7 Other Applications

9 Global Gene Silencing Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Research Institutions
  • 9.4 CROs & CDMOs
  • 9.5 Hospitals & Diagnostic Labs
  • 9.6 Other End Users

10 Global Gene Silencing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Alnylam Pharmaceuticals
  • 12.2 Ionis Pharmaceuticals
  • 12.3 Arrowhead Pharmaceuticals
  • 12.4 Silence Therapeutics
  • 12.5 Dicerna Pharmaceuticals
  • 12.6 Sirnaomics
  • 12.7 Arbutus Biopharma
  • 12.8 Olix Pharmaceuticals
  • 12.9 Benitec Biopharma
  • 12.10 Sylentis
  • 12.11 Genevant Sciences
  • 12.12 RXi Pharmaceuticals
  • 12.13 Intellia Therapeutics
  • 12.14 Editas Medicine
  • 12.15 Beam Therapeutics

List of Tables

  • Table 1 Global Gene Silencing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Gene Silencing Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Gene Silencing Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 4 Global Gene Silencing Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 5 Global Gene Silencing Market Outlook, By Oligonucleotides & RNA Molecules (2024-2032) ($MN)
  • Table 6 Global Gene Silencing Market Outlook, By Software & Bioinformatics Tools (2024-2032) ($MN)
  • Table 7 Global Gene Silencing Market Outlook, By Gene Silencing Services (2024-2032) ($MN)
  • Table 8 Global Gene Silencing Market Outlook, By Other Product & Services (2024-2032) ($MN)
  • Table 9 Global Gene Silencing Market Outlook, By Mechanism (2024-2032) ($MN)
  • Table 10 Global Gene Silencing Market Outlook, By Transcriptional Gene Silencing (2024-2032) ($MN)
  • Table 11 Global Gene Silencing Market Outlook, By Post-Transcriptional Gene Silencing (2024-2032) ($MN)
  • Table 12 Global Gene Silencing Market Outlook, By Epigenetic Modulation (2024-2032) ($MN)
  • Table 13 Global Gene Silencing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 14 Global Gene Silencing Market Outlook, By RNA Interference (RNAi) (2024-2032) ($MN)
  • Table 15 Global Gene Silencing Market Outlook, By Antisense Oligonucleotides (ASOs) (2024-2032) ($MN)
  • Table 16 Global Gene Silencing Market Outlook, By CRISPR Interference (CRISPRi) (2024-2032) ($MN)
  • Table 17 Global Gene Silencing Market Outlook, By Epigenetic Silencing (2024-2032) ($MN)
  • Table 18 Global Gene Silencing Market Outlook, By siRNA/shRNA Delivery Systems (2024-2032) ($MN)
  • Table 19 Global Gene Silencing Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global Gene Silencing Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 21 Global Gene Silencing Market Outlook, By Therapeutics Manufacturing (2024-2032) ($MN)
  • Table 22 Global Gene Silencing Market Outlook, By Functional Genomics (2024-2032) ($MN)
  • Table 23 Global Gene Silencing Market Outlook, By Target Validation (2024-2032) ($MN)
  • Table 24 Global Gene Silencing Market Outlook, By Disease Modeling (2024-2032) ($MN)
  • Table 25 Global Gene Silencing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Gene Silencing Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Gene Silencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 28 Global Gene Silencing Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
  • Table 29 Global Gene Silencing Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
  • Table 30 Global Gene Silencing Market Outlook, By Hospitals & Diagnostic Labs (2024-2032) ($MN)
  • Table 31 Global Gene Silencing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.